Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ocumension Therapeutics ( (HK:1477) ) just unveiled an update.
Ocumension Therapeutics announced a 75.4% increase in revenue for the first half of 2025, reaching RMB294.0 million, driven by the growth of key ophthalmic products and successful integration of products from Alcon. Despite the revenue growth, the company reported an adjusted net loss of RMB108.0 million due to increased costs. The approval of new products, including ZERVIATE and OT-703, and the commencement of a phase III clinical trial for OT-802, highlight the company’s ongoing efforts to expand its product portfolio and strengthen its market position in China.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company incorporated in the Cayman Islands, focusing on the ophthalmic industry. It specializes in the development and commercialization of eye-related pharmaceutical products and services, with a significant market presence in China.
Average Trading Volume: 8,673,592
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.83B
For an in-depth examination of 1477 stock, go to TipRanks’ Overview page.